

# Persistence of Beta-Blocker Treatment After a Heart Attack

**Category:** Other  
**Program:** Adult

## Measure Requirements

Members who were hospitalized with a diagnosis of acute myocardial infarction (AMI), discharged alive on or between July 1 of the year prior to the measurement year (2023) and June 30 of the measurement year (2024) and who received persistent beta-blocker treatment for six months (at least 135 days) after discharge.



## Member Requirements

Members who were with a practice for 11 consecutive months within the measurement year (2024) and who were 18 and older as of December 31 of the measurement year (2024) who were discharged alive from an acute inpatient setting with an AMI on or between July 1 of the year prior to the measurement year (2023) and June 30 of the measurement year (2024) through 179 days after discharge. If there is more than one episode of AMI during the time frame, only the initial episode discharge date is used.



| QPM Targets*  |              |
|---------------|--------------|
| <b>Band 1</b> | 72% – 100%   |
| <b>Band 2</b> | 63% – 71.99% |
| <b>Band 3</b> | 60% – 62.99% |
| <b>Band 4</b> | 55% – 59.99% |
| <b>Band 5</b> | <55%         |

See payment details in section 5 of guide.

\*These targets include the performance of more than one measure. This represents the combined performance for all the measures in this category.

## Options to close Care Gaps

- **Option 1:** Claim/encounter submission with appropriate coding and dispense of a beta-blocker medication.

### *Beta-blocker medications*

| Description                             | Prescription   |   |                         |
|---|--|---|-------------------------|
| <b>Noncardioselective beta-blockers</b> | Carvedilol<br>Labetalol<br>Nadolol<br>Pindolol   | Propranolol<br>Timolol<br>Sotalol                                 |                         |
| <b>Cardioselective beta-blockers</b>    | Acebutolol<br>Atenolol   | Betaxolol<br>Bisoprolol   | Metoprolol<br>Nebivolol |
| <b>Antihypertensive combinations</b>    | Atenolol-chlorthalidone<br>Bendroflumethiazide-nadolol<br>Bisoprolol-hydrochlorothiazide | Hydrochlorothiazide-metoprolol<br>Hydrochlorothiazide-propranolol |                         |

- **Option 2:** Claim/encounter submission with appropriate exclusion coding for a dispensed dementia or asthma medication.

### *Dementia exclusion medications*

| Description  | Prescription        |             |              |
|--|---------------------|-------------|--------------|
| <b>Cholinesterase inhibitors</b>                   | Donepezil           | Galantamine | Rivastigmine |
| <b>Miscellaneous central nervous system agents</b> | Memantine           |             |              |
| <b>Dementia combinations</b>                       | Donepezil-memantine |             |              |

### *Asthma exclusion medications*

| Description                        | Prescription                 |                            |                           |                        |
|------------------------------------|------------------------------|----------------------------|---------------------------|------------------------|
| <b>Bronchodilator Combinations</b> | Budesonide-formoterol        | Formoterol-mometasone      | Fluticasone-salmeterol    | Fluticasone-vilanterol |
| <b>Inhaled corticosteroids</b>     | Beclomethasone<br>Budesonide | Ciclesonide<br>Flunisolide | Fluticasone<br>Mometasone |                        |

CPT Copyright 2017 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.